As the U.S. Judicial Panel on Multidistrict Litigation (JPML) prepares to determine whether federal lawsuits over Pradaxa should be consolidated, new claims continue to be filed on behalf of individuals around the country who claim to have experienced severe – and in some cases fatal – bouts of internal bleeding after taking the drug.
Free Pradaxa Lawsuit Evaluation: If you or a loved one has been injured by Pradaxa, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer and our lawyers can help.
What’s the problem?
July 25, 2012 – At a hearing tomorrow before the JPML, lawyers for Boehringer and various plaintiffs will present arguments over the consolidation of Pradaxa lawsuits into a multidistrict litigation (MDL), including what the most appropriate venue will be for the cases to be heard.
MDLs are common in complex pharmaceutical litigation, where a large number of lawsuits are filed involving similar allegations. Consolidation is intended to reduce duplicative discovery, avoid inconsistent rulings from different judges, and to serve the convenience of all parties involved in the litigation.
Following tomorrow’s hearing, the JPML will decide whether a Pradaxa MDL is appropriate, and determine the best venue for the litigation. If an MDL is initiated, all Pradaxa lawsuits will be transferred to the designated location for pretrial coordination.
Although the complaints in an MDL are handled in a coordinated manner, unlike a class action, each claim remains its own case. In the event that a settlement or other resolution cannot be reached in the litigation, the claims will be sent back to the original district where they were filed to await an individual trial date.
Since it was first approved by the FDA, Boehringer has marketed Pradaxa as superior to Coumadin (generic: warfarin) for the prevention of strokes among patients with atrial fibrillation. The company claims that Pradaxa is easier to use because it requires less intensive patient monitoring. However, unlike Coumadin, where internal bleeding events can be counteracted with a single dose of vitamin K, there is no such antidote available with Pradaxa. As a result, thousands of patients around the country being treated with the drug have reported severe, uncontrollable bleeding events which often result in permanent injury or death.
According to the Institute for Safe Medication Practices (ISMP), which kept a record of all AERS submitted to the FDA in 2011, there were 2,367 reports of hemorrhage and 542 deaths among Pradaxa patients last year. By comparison, Coumadin was only associated with 1,106 AERS and 72 patient deaths, despite the fact that it has been around for over a half century, and is far more widely used than Pradaxa.
Do I Have a Pradaxa Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Pradaxa lawsuits. We are handling individual litigation nationwide and currently accepting new cases in all 50 states.
Free Confidential Case Evaluation: Again, if you or a loved one was injured by Pradaxa, you should contact our law firm immediately. You may be entitled to compensation by filing a suit and our lawyers can help.